

S/N 10/000,452

IFW

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: McGrogan

Examiner: Robert C. Hayes

Serial No.: 10/000,452

Group Art Unit: 1649

Filed: December 4, 2001

Docket: LAY-007ORD

Title: Production and Use of Dopaminergic cells to treat dopaminergic deficiencies

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the referenced materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b)(3), Applicants are filing this IDS before the mailing of the first Office action on the merits in this application. Therefore, it is believed that no fee is due. The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication or if a fee is due.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicants believe that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicants have not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicants respectfully request that notice of such requirement be directed to Applicants' below-

**INFORMATION DISCLOSURE STATEMENT**

Serial No :10/000,452

Filing Date: December 4, 2001

Title: Production and Use of Dopaminergic cells to treat dopaminergic deficiencies

Page 2

Dkt: LAY-007ORD

signed representative. Applicants acknowledge the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

Respectfully submitted,

By their Representative,

Date March 14, 2006  
The Luther Law Firm, PLC  
12198 E. Columbine Dr.  
Scottsdale, AZ 85259  
Tel: 480-275-8302  
Fax: 480-275-8303

By Barbara J. Luther  
Barbara J. Luther  
Reg. No. 33,954

**CERTIFICATE UNDER 37 CFR 1.8:** The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 14 day of March, 2006.

Barbara J. Luther  
Name

Barbara J. Luther  
Signature

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***Complete if Known*

Application Number	10/000,452
Filing Date	December 4, 2001
First Named Inventor	McGrogan
Art Unit	1649
Examiner Name	Robert C. Hayes

(Use as many sheets as necessary)

Sheet

1

of

5

Attorney Docket No: LAY-007ORD

**US PATENT DOCUMENTS**

Examiner Initial *	Cite No	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
		US-5175103	12/29/1992	Lee, Virginia et al.	10/21/1991
		US-5411883	05/02/1995	Boss, Barbara D., et al.	08/12/1992
		US-5654183	08/05/1997	Anderson et al.	01/28/1994
		US-5750376	05/12/1998	Weiss, Samuel et al.	06/07/1995
		US-5753506	05/19/1998	Johe	09/25/1996
		US-5843780	12/01/1998	Thomson	01/18/1996
		US-5981165	11/09/1999	Weiss, Samuel	06/07/1995

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
	WO-00/06700	02/10/2000	McGrogan, Michael , et al.	
	WO-90/06757	06/28/1990	Gage, Fred H., et al.	
	WO-96/15224	05/23/1996	Weiss, Samuel , et al.	
	WO-97/33470	09/18/1997	Sanberg, Paul R.	
	WO-99/56759	11/11/1999	McGrogan, Michael	
	WO-94/10292	05/11/1994	Weiss, Samuel , et al.	
	WO-96/15224	05/23/1996	Weiss, Samuel	
	WO-97/33470	09/18/1997	Sanberg, Paul R., et al.	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ADAMS, F.S. , et al., "Characterization and transplanted of two neuronal cell lines with dopaminergic properties", <u>Chem. Res.</u> 21(5), (1996),619-27	
		ANDREWS, P. , et al., "Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2", <u>Lab. Invest.</u> 50(2), (1984),147-62	
		BAKER, K.A. , "Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's Disease", <u>Exp. Neurol.</u> 162(2), (2000),350-60	
		BECKER, R. , et al., "Lithium enhances the proliferation of HL-60 promyelocytic leukemia cells", <u>Leukemia Res.</u> 14(10), (1990),879-84	
		CENTENO, F. , et al., "Partial lithium-associated protection against apoptosis induced by C2-ceramide in cerebellar granule neurons", <u>Neuroreport</u> 9(18), (1998),4199-4203	

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<i>Complete if Known</i>	
				Application Number	10/000,452
				Filing Date	December 4, 2001
				First Named Inventor	McGrogan
				Art Unit	1649
				Examiner Name	Robert C. Hayes
Sheet	2	of	5	Attorney Docket No: LAY-007ORD	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		CHEN, G. , et al., "Increase in AP-1 transcription factor DNA binding activity by valproic acid", <u>Neuropsychopharmacology</u> 16(2), (1997),238-45	
		D'MELLO, S.R. , et al., "Lithium induces apoptosis in immature cerebellar granule cells but promotes survival of mature neurons", <u>Exp. Cell Res.</u> 211(2), (1994),332-38	
		FRIEDMAN, et al., "Effect of lithium on brain dopamine", <u>Nature</u> 243, (1973),520-21	
		GARCIA-PEREZ, JULIA , et al., "Lithium induces morphological differentiation of mouse neuroblastoma cells", <u>J. Neurosci. Res.</u> 57, (1999),261-70	
		GRIGNON, S. , et al., "Tyrosine kinase inhibitors and cycloheximide inhibit lithium protection of cerebellar granule neurons switched to non-depolarizing medium", <u>Eur. J. Pharmacol</u> 315(1), (1996),111-14	
		HARTLEY, R. , et al., "Differential effects of spinal cord gray and white matter on process outgrowth from grafted human NTERA2 neurons (NT2N, hNT)", <u>J. Comparative Neurol.</u> 415(3), (1999),404-17	
		HASGEKAR, N.N. , et al., "Lithium inhibits growth in a murine neural precursor cell line", <u>Cell Biol.</u> 20(12), (1996),781-86	
		HOLLANDER, B. A., et al., "Lithium chloride alters cytoskeletal organization in growing, but not mature, cultured chick sensory neurons", <u>J. Neurosci. Res.</u> 28(3), (1991),332-42	
		HONG, M. , et al., "Lithium reduces tau phosphorylation by inhibition of glycogen synthetase kinase-3", <u>J. Biol. Chem.</u> 272(40), (1997),25326-32	
		IACOVITTI, LORRAINE , "Expression of tyrosine hydroxylase in newly differentiated neurons from a human cell line (hNT)", <u>Neuroreport</u> 8, (1997),1471-4	
		JOHNSON, G. , "Lithium in depression: a review of the antidepressant and prophylactic effects of lithium", <u>Australian and New Zealand J. Psychiatry</u> 21(3), (1987),356-65	
		KAPLAN, H.I. , "Ch. 9, Mood Disorders", <u>Concise Textbook of Clinical Psychiatry</u> , Williams & Walkins, (1996),159-188	
		LA MOUREUX, P. , et al., "Extracellular matrix allows PC12 neurite elongation in the absence of microtubules", <u>J. Cell Biol.</u> 110(1), (1990),71-79	
		LANGEVALD, CORNELIUS H., et al., "Cultured rat striatal and cortical astrocytes protect mesencephalic dopaminergic neurons against hydrogen peroxide toxicity independent of their effect on neuronal development", <u>Neurosci. Lett.</u> 192, (1995),13-16	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Substitute for form 1449A/PTO					
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Complete if Known</i>	
				<b>Application Number</b>	10/000,452
				<b>Filing Date</b>	December 4, 2001
				<b>First Named Inventor</b>	McGrogan
				<b>Art Unit</b>	1649
				<b>Examiner Name</b>	Robert C. Hayes
(Use as many sheets as necessary)					
Sheet	3	of	5	Attorney Docket No: LAY-007ORD	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		LEE, V., et al., "hNT neurons: human postmitotic CNS neurons", <u>Strat. Mol. Biol.</u> 7, (none),28-31	
		LI, "Selective inhibition of the expression of signal transduction proteins by lithium in nerve growth factor-differentiated PC12 cells", <u>J. Neurosci.</u> 65, (1995),2500-08	
		LINDVALL, "Engineering neurons for Parkinson's disease", <u>Nature Biotechnology</u> 17, (1999),635-6	
		LING, "Differentiation of mesencephalic progenitor cells...", <u>Exp. Neurol.</u> 149, (1998),411-23	
		LOPEZ-LOZANO, J. , "Long-term improvement in patients with severe Parkinson's Disease after implantation of fetal ventral mesencephalic tissue in a cavity of the caudate nucleus: 5-yr follow up in 10 patients.", <u>J. Neurosurg.</u> 86, (1997),931-42	
		LUCAS, FIONA R., et al., "Inhibition of GSK-3 beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium", <u>J. Cell Sci.</u> 111, (1998),1351-61	
		LUCAS, F. , et al., "WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons", <u>Dev. Biol.</u> 192(1), (1997),31-44	
		MENA, MARIA A., "Effects of dibutyryl cyclic AMP and retinoic acid on the differentiation of dopamine neurons: prevention of cell death by dibutyryl cyclic AMP", <u>J Neurochem</u> 65(6), (1995),2612-20	
		MENDEZ, "Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplants", <u>J. Neurosci.</u> 16, (1996),7216-27	
		MIYAZONO, M. , et al., "Long-term integration and neuronal differentiation of human embryonal carcinoma cells (NTera-2) transplanted into the caudatoputamen of nude mice", <u>J. Compar. Neurol.</u> 376(4), (1996),603-13	
		MURRAY, R.K. , "Ch. 64. Biochemical basis of some neuropsychiatric disorders", <u>Harper's Biochemistry</u> 24 ed., Appleton & Lange, (1996),793-813	
		NONAKA, S. , et al., "Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx", <u>J. Neurochem.</u> 69(5), (1998),2642-47	
		NONAKA, S. , et al., "Lithium protects rat cerebellar granule cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine", <u>J. Pharmacol. Exp. Therap.</u> 286(1), (1998),539-47	

EXAMINER

DATE CONSIDERED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***Complete if Known*

<b>Application Number</b>	10/000,452
<b>Filing Date</b>	December 4, 2001
<b>First Named Inventor</b>	McGrogan
<b>Art Unit</b>	1649
<b>Examiner Name</b>	Robert C. Hayes

(Use as many sheets as necessary)

Sheet

4

of

5

Attorney Docket No: LAY-007ORD

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		NONAKA, S. , et al., "Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats", <u>Neuroreport</u> 9(9), (1998),2081-84	
		ORKIN, S. H., "Report and recommendations of the panel to assess the NIH investment in research on gene therapy", <u>December</u> , (1995),1-41	
		OZAKI, N. , et al., "Lithium increases transcription factor binding to AP-1 and cyclic AMP-resonsive element in cultured neurons and rat brain", <u>J. Neurochem</u> 69(6), (1997),2336-44	
		PEKOSZ, "Induction of apoptosis by La Crosse virua infection and role of neuronal differentiation and human bcl-2 expression in its prevention", <u>J. Virology</u> 70, (1996),5329-5335	
		PLEASURE, SAMUEL , "Pure, postmitotic, polarized human neurons derived from NTera 2 cells provide a system for expressing exogenous proteins in terminally differentiated neurons", <u>J Neurosci</u> 12, (1992),1802-15	
		ROSENBLAD, "Glial cell lline-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts", <u>Neuroscience</u> 75, (1996),979-85	
		SANBERG, PAUL R., "Testis-derived Sertoli cells have a trophic effect on dopamine neurons and alleviate hemiparkinsonsism in rats", <u>Nature Medicine</u> 3, (1997),1129-32	
		SAPORTA, S. , et al., "In vitro and in vivo characterization of hNT neuron neurotransmitter phenotypes", <u>Brain Res. Bull.</u> 53(3), (2000),263-68	
		SEGAL, D. , et al., "Alterations in behavior and catecholamine biosynthesis induced by lithium", <u>Nature</u> 254 (5495), (1975),58-59	
		SENTMAN, "bcl-2 inhibits multiple forms of apoptosis... (abstract)", <u>Cell</u> 67(5), (1991),879-88	
		TERAO, TAKESHI , "Lithium Chloride Stimulates Catecholamine Synthesis and secretion in Cultured bovine adrenal medullary cells", <u>Biol Psychiatry</u> 31, (1992),1038-49	
		UNLAP, M.T. , et al., "Lithium attenuates nerve growth factor-induced activation of AP-1 DNA binding activity in PC12 cells", <u>Neuropsychopharmacology</u> 17(1), (1997),12-17	
		VERMA, I. M., "Gene therapy - promises, problems and prospects", <u>Nature</u> 389, (1997),239-42	
		WAGNER, "Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by Type 1 astrocytes", <u>Nature Biotechnology</u> 17, (1999),635-59	

**EXAMINER****DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Complete if Known</i>	
				<b>Application Number</b>	10/000,452
				<b>Filing Date</b>	December 4, 2001
				<b>First Named Inventor</b>	McGrogan
				<b>Art Unit</b>	1649
				<b>Examiner Name</b>	Robert C. Hayes
(Use as many sheets as necessary)					
Sheet	5	of	5	Attorney Docket No: LAY-007ORD	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
		YUAN, P.X. , et al., "The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth", <u>J. Biol. Chem.</u> 276(34), (2001),31674-83		
		ZHANG, X., et al., "Inhibitory actions of ropivacaine on tumor necrosis factor-alpha-induced leukocyte adhesion and tissue accumulation in vivo", <u>Eur. J. Pharmacol.</u> 392(1/2), (2000),R1-R3		
		ZIGOVA, T. , et al., "Apoptosis in cultured hNT neurons", <u>Dev. Brain Res.</u> 127, (2001),63-70		
		ZIGOVA, T. , et al., "Dopaminergic phenotype of hNT cells in vitro", <u>Dev. Brain Res.</u> 122, (2000),87-90		
		ZIGOVA, T. , et al., "Lithium chloride induces the expression of tyrosine hydroxylase in hNT neurons", <u>Exp. Neurol.</u> 157(2), (1999),251-58		
		ZIGOVA, T. , et al., "Neural stem cells for brain repair", <u>Science &amp; Medicine</u> September/October, (1999),18-27		

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached